Skip to main content
INKON Life Technology Co., Ltd. logo

INKON Life Technology Co., Ltd. — Investor Relations & Filings

Ticker · 300143 ISIN · CNE100000XF6 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,851 across all filing types
Latest filing 2024-06-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300143

About INKON Life Technology Co., Ltd.

https://www.inkonlife.com

INKON Life Technology Co., Ltd. specializes in the development and manufacture of advanced medical equipment and digital healthcare solutions. The company focuses on two primary sectors: radiotherapy equipment and digital medical services. Its core product portfolio includes high-precision radiotherapy systems, such as the Gamma Knife, and medical infusion systems. INKON Life leverages Internet of Things (IoT) technology to provide integrated digital hospital solutions, aiming to improve clinical efficiency and patient outcomes. The company serves oncology centers and medical institutions by providing comprehensive cancer treatment solutions and smart healthcare management platforms. By combining medical engineering with digital innovation, INKON Life focuses on the modernization of radiotherapy and the digital transformation of healthcare delivery.

Recent filings

Filing Released Lang Actions
盈康生命科技股份有限公司与国泰君安证券股份有限公司关于申请向特定对象发行股票的审核问询函的回复(修订稿)(2023年年报及2024年一季报数据更新稿)
Capital/Financing Update Classification · 95% confidence The document is a detailed response to a regulatory inquiry from the Shenzhen Stock Exchange regarding a company's application for a specific share issuance to targeted investors. It includes extensive disclosures about the company's business activities, regulatory compliance, and operational details, particularly focusing on medical and healthcare services. The document references a formal inquiry letter, regulatory requirements, and provides comprehensive answers to multiple questions, indicating it is a regulatory filing related to a capital raising process. It is not a financial report like an annual or interim report, nor is it a simple announcement or presentation. The content aligns with a Capital/Financing Update, as it pertains to the application and approval process for a specific share issuance to targeted investors, including regulatory responses and compliance confirmations.
2024-06-25 Chinese
国泰君安证券股份有限公司关于盈康生命科技股份有限公司向特定对象发行股票之上市保荐书(2023年年报及2024年一季报更新稿)
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" (Listing Sponsorship Letter) issued by Guotai Junan Securities Co., Ltd. regarding a specific issuance of shares by 盈康生命科技股份有限公司 (INKON Life Technology Co., Ltd.) to specific investors. It contains detailed information about the issuer, the issuance plan, financial data for recent years, risk factors, and regulatory compliance statements. The document is a formal sponsorship letter related to a specific share issuance to designated investors, including detailed financial data and risk disclosures. This type of document is typically associated with capital raising activities and financing updates rather than a full annual report or audit report. It is not a simple announcement or a proxy statement, but a comprehensive document supporting a capital issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full report, not just an announcement or certification.
2024-06-25 Chinese
国泰君安证券股份有限公司关于盈康生命科技股份有限公司向特定对象发行股票之发行保荐书(2023年年报及2024年一季报更新稿)
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" which translates to "Sponsorship Letter for Stock Issuance to Specific Objects". It is issued by Guotai Junan Securities Co., Ltd. as the sponsor for a specific stock issuance by INKON Life Technology Co., Ltd. The document contains detailed information about the stock issuance, the sponsor's responsibilities, legal compliance, internal review procedures, financial data, shareholder structure, and regulatory compliance. It is a comprehensive document related to a capital raising event through a non-public stock issuance to specific investors. The document is not a general annual report, earnings release, or management discussion but specifically focuses on the issuance and sponsorship of new shares to specific investors. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and financing activities. The document length is substantial (15,000 characters), and it contains substantive content rather than just an announcement or certification, so it is not an RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2024-06-25 Chinese
和信会计师事务所(特殊普通合伙)关于盈康生命科技股份有限公司申请向特定对象发行股票的审核问询函回复(2023年年报及2024年一季报数据更新稿)
Capital/Financing Update Classification · 95% confidence The document is a detailed response to a regulatory inquiry regarding a company's application for a specific stock issuance. It includes extensive financial data, business environment analysis, goodwill impairment risk assessment, and compliance with regulatory requirements. The presence of audit firm involvement, detailed financial and operational analysis, and references to a prospectus (募集说明书) indicate this is part of a regulatory filing related to a capital raising event. The document is not a full annual or interim report but a formal reply to a stock issuance review inquiry, which fits the category of Capital/Financing Update (CAP). The length and detail confirm it is not a mere announcement or certification, but a substantive regulatory filing related to financing.
2024-06-25 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the number of shares repurchased, prices, total amount spent, compliance with regulatory rules, and future intentions to continue the repurchase. It references prior announcements and regulatory guidelines but does not contain financial statements or earnings data. The document length is short (1323 characters) and focuses on the update of share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2024-06-03 Chinese
国泰君安证券股份有限公司关于盈康生命科技股份有限公司向特定对象发行股票之发行保荐书（2023年年报及2024年一季报更新稿）
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) by Guotai Junan Securities Co., Ltd. regarding a specific stock issuance by INKON Life Technology Co., Ltd. It contains detailed information about the securities issuance, the sponsor's responsibilities, legal compliance, internal review procedures, financial data, shareholder structure, and regulatory compliance related to a specific private placement of shares. The document is a formal sponsorship and recommendation letter for a specific securities issuance, which is a type of capital raising activity. It is not a general annual or quarterly report, audit report, earnings release, or other types of filings. It is a detailed document related to a capital/financing update, specifically the issuance of shares to specific investors. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the actual sponsorship document, not just an announcement or a certification, so it is not RPA or RNS.
2024-05-15 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.